What is the significance of HUTCHMED (NASDAQ:HCM) starting a Phase III trial for HMPL-760?

HUTCHMED has moved HMPL-760 into a registrational Phase III clinical trial, which is the final stage of testing required before seeking regulatory approval. This transition indicates that earlier Phase II data provided enough evidence of safety and efficacy to justify a large-scale, randomized study. For investors, this marks a de-risking milestone as the drug moves closer to potential commercialization in the Chinese oncology market.

What specific condition is HUTCHMED (NASDAQ:HCM) targeting with this study?

The trial evaluates HMPL-760 as a treatment for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). DLBCL is the most common aggressive form of non-Hodgkin lymphoma in China, and there is currently a high unmet medical need for patients who cannot undergo stem cell transplants. This positioning allows HUTCHMED to target a significant patient population with limited existing high-efficacy treatment options.

How does HMPL-760 differ from earlier-generation BTK inhibitors?

HMPL-760 is a third-generation, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor designed to overcome resistance issues common in first- and second-generation treatments. Specifically, it is engineered to target the C481S mutation, which often causes patients to stop responding to earlier covalent inhibitors. This technical advantage could give HUTCHMED a competitive edge in treating "refractory" patients who have failed other therapies.

What are the key metrics and primary endpoints for the HMPL-760 Phase III trial?

The study (NCT07409428) focuses on two primary endpoints: investigator-assessed progression-free survival (PFS) and overall survival (OS). Secondary metrics include the objective response rate (ORR), complete response rate (CRR), and the duration of response (DoR). Success in these areas would demonstrate that the drug not only shrinks tumors but also significantly extends the lives of DLBCL patients compared to the placebo group.

What is the scale and structure of the HUTCHMED (NASDAQ:HCM) clinical trial?

This is a randomized, double-blind, placebo-controlled study expected to enroll approximately 240 patients across multiple clinical sites in China. Patients will receive either HMPL-760 or a placebo in combination with the R-GemOx chemotherapy regimen (rituximab, gemcitabine, and oxaliplatin). The use of a double-blind, placebo-controlled design is the "gold standard" for clinical evidence and is typically required for standard-of-care changes.

Health

Image for illustrative purposes only. Not a real photo.

HUTCHMED doses first patient in registrational Phase III trial for lymphoma therapy

Written by Isaac FrancisPublished Mar 23, 2026, 12:00 AMLast Updated Jul 6, 2026, 10:43 AM

HUTCHMED (NASDAQ:HCM) announced the initiation of a registrational Phase III clinical trial for HMPL-760, an investigational non-covalent Bruton’s tyrosine kinase (BTK) inhibitor.

The first patient was dosed on March 20, 2026, in a study evaluating the efficacy and safety of HMPL-760 in combination with the R-GemOx regimen (rituximab, gemcitabine, and oxaliplatin) for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

The randomized, double-blind, placebo-controlled study (NCT07409428) is designed to enroll approximately 240 patients across multiple clinical sites in China.

The primary endpoints are investigator-assessed progression-free survival (PFS) and overall survival (OS).

Secondary outcome measures include objective response rate (ORR), complete response rate (CRR), duration of response (DoR), and safety and pharmacokinetics (PK) profiles.

HMPL-760 is a highly potent and selective third-generation BTK inhibitor designed to overcome resistance seen with earlier-generation covalent inhibitors, specifically those harboring the C481S mutation.

DLBCL is the most common form of aggressive non-Hodgkin lymphoma in China, and the current standard of care for patients who are ineligible for stem cell transplantation remains a significant unmet medical need.

The initiation of this Phase III trial follows encouraging results from earlier Phase II testing, which demonstrated manageable safety and preliminary clinical benefit.

HUTCHMED doses first patient in registrational Phase III trial for lymphoma therapy

Perguntas frequentes

Ativos relacionados a notícia